Three consecutive boards HPGC Renmintongtai Pharmaceutical Corporation (600829.SH): Main Business has not undergone significant changes.

HPGC Renmintongtai Pharmaceutical Corporation (600829.SH) issued a risk warning announcement, the company is a pharmaceutical distribution enterprise, mainly engaged in the operation of pharmaceutical wholesale...

Zhitong FinanceDec 16 05:01 ET

Are Robust Financials Driving The Recent Rally In HPGC Renmintongtai Pharmaceutical Corporation's (SHSE:600829) Stock?

Simply Wall StDec 12 21:19 ET

Improved Earnings Required Before HPGC Renmintongtai Pharmaceutical Corporation (SHSE:600829) Stock's 30% Jump Looks Justified

Simply Wall StNov 8 17:11 ET

Third Quarter Report 2024

SZSIOct 21 12:00 ET · Announcements

hpgc renmintongtai pharmaceutical corporation (600829.SH) released its performance for the first three quarters, with a net income of 0.206 billion yuan, a 14.36% year-on-year decrease.

hpgc renmintongtai pharmaceutical corporation (600829.SH) disclosed the third quarter report for 2024, achieving revenue of 76...

Zhitong FinanceOct 21 04:44 ET

hpgc renmintongtai pharmaceutical corporation (600829.SH): net income in the first three quarters was 0.206 billion yuan, a year-on-year decrease of 14.36%.

Gelonghui October 21st丨Hpgc Renmintongtai Pharmaceutical Corporation (600829.SH) released the third quarter report, with revenue of 7.678 billion yuan, a year-on-year decrease of 1.88%, net income of 0.206 billion yuan, a year-on-year decrease of 14.36%, non-GAAP net income of 0.19 billion yuan, a year-on-year decrease of 17.16%, and basic earnings per share of 0.3552 yuan.

Gelonghui FinanceOct 21 04:43 ET